These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 28737758)
1. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J; Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758 [TBL] [Abstract][Full Text] [Related]
2. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913 [TBL] [Abstract][Full Text] [Related]
3. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262 [TBL] [Abstract][Full Text] [Related]
4. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887 [TBL] [Abstract][Full Text] [Related]
5. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Holden SE; Kapik B; Beiderbeck AB; Currie CJ Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759 [No Abstract] [Full Text] [Related]
6. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years. Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139 [TBL] [Abstract][Full Text] [Related]
9. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C; Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062 [TBL] [Abstract][Full Text] [Related]
10. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN Panos GD; Arruti N; Patra S Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704 [TBL] [Abstract][Full Text] [Related]
11. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema. Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148 [TBL] [Abstract][Full Text] [Related]
12. Fluocinolone acetonide for the treatment of diabetic macular edema. Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565 [TBL] [Abstract][Full Text] [Related]
13. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472 [TBL] [Abstract][Full Text] [Related]
14. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials. Parrish RK; Campochiaro PA; Pearson PA; Green K; Traverso CE; Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):426-35. PubMed ID: 27183546 [TBL] [Abstract][Full Text] [Related]
15. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Currie CJ; Holden SE; Berni E; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143 [TBL] [Abstract][Full Text] [Related]
17. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. Elaraoud I; Andreatta W; Kidess A; Bhatnagar A; Tsaloumas M; Quhill F; Yang Y BMC Ophthalmol; 2016 Jan; 16():3. PubMed ID: 26728265 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Holden SE; Currie CJ; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149 [TBL] [Abstract][Full Text] [Related]